SRR8392899
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.420
- TNFA_SIGNALING_VIA_NFKB+0.390
- E2F_TARGETS+0.330
- OXIDATIVE_PHOSPHORYLATION+0.300
- MYC_TARGETS_V2+0.290
- P53_PATHWAY+0.290
- DNA_REPAIR+0.240
- IL6_JAK_STAT3_SIGNALING+0.230
- INFLAMMATORY_RESPONSE+0.230
- INTERFERON_GAMMA_RESPONSE+0.220
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.300
- PANCREAS_BETA_CELLS-0.210
- CHOLESTEROL_HOMEOSTASIS-0.150
- APICAL_JUNCTION-0.120
- WNT_BETA_CATENIN_SIGNALING-0.090
- MYOGENESIS-0.070
- ESTROGEN_RESPONSE_EARLY-0.050
- NOTCH_SIGNALING-0.050
- PI3K_AKT_MTOR_SIGNALING-0.050
- GLYCOLYSIS-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0154 | Med | Medulloblastoma | 0.825 |
| 2 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.824 |
| 3 | SRR934888 | — | — | 0.815 |
| 4 | BS_8T7DZV2F | medulloblastoma | — | 0.808 |
| 5 | BS_GJNCYABP | ATRT | — | 0.790 |
| 6 | TCGA-33-4566-01A-01R-1443-07 | — | cohortA1 | 0.789 |
| 7 | SRR6013496 | — | cohortA4 | 0.785 |
| 8 | TCGA-H7-8501-01A-11R-2403-07 | — | — | 0.782 |
| 9 | BS_8GW1TMV2 | Med | Medulloblastoma | 0.778 |
| 10 | TCGA-CV-7099-01A-41R-2016-07 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |